Shots:
Under the terms of the agreement, Inceptor Bio will receive an exclusive license for the novel iPSC platform developed in collaboration with the University of Minnesota by accelerating Inceptor Bio’s cell therapies platforms for the treatment of difficult-to-treat cancers
Inceptor Bio plans to include the newly developed iPSC platform into its proprietary K62 for CAR_M therapy which increases the phagocytic capabilities of macrophages & supports the M1 anti-tumor phenotype along with the M83 costimulatory domain
iPSC-derived cell therapies have the potential to enable the next frontier of cell therapies & therefore will further advance Inceptor Bio’s multiple cell therapy products
Ref: PR Newswire | Image: PR Newswire
